19:27 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Blueprint debuts selective ALK2 inhibitor for rare musculoskeletal disease

Blueprint Medicines Corp. (NASDAQ:BPMC) provided the first glimpse of its preclinical ALK2 inhibitor program, BLU-782, when it presented data at the American Society for Bone and Mineral Research (ASBMR) meeting in Montreal on Sept. 30....
15:30 , Sep 30, 2018 |  BC Extra  |  Preclinical News

Blueprint Medicines unveils preclinical data for rare bone disease program

Blueprint Medicines Corp. (NASDAQ:BPMC) provided the first glimpse of its preclinical ALK2 inhibitor program, BLU-782, when it presented data at the American Society for Bone and Mineral Research (ASBMR) meeting in Montreal on Sunday. Blueprint...
19:43 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

Pfizer ends Phase II trials of DMD candidate

Pfizer Inc. (NYSE:PFE) terminated two Phase II trials of domagrozumab (PF-06252616) to treat Duchenne muscular dystrophy after one of the studies missed its primary endpoint. The company will evaluate the data to determine next steps...
15:47 , Aug 30, 2018 |  BC Extra  |  Clinical News

Pfizer ends Phase II trials of DMD candidate

Pfizer Inc. (NYSE:PFE) terminated two Phase II trials of domagrozumab (PF-06252616) to treat Duchenne muscular dystrophy after one of the studies missed its primary endpoint. The company will evaluate the data to determine next steps...
03:00 , Aug 10, 2018 |  BC Innovations  |  Targets & Mechanisms

Getting to function

A new target for sarcopenia that increases muscle function directly, in addition to adding muscle mass, could help address calls from patients and regulators to make functional recovery central to drug development in the indication....
20:06 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Patient sample, cell culture and mouse studies suggest inhibiting activin signaling could enhance the efficacy of platinum-based chemotherapy in KRAS-mutant lung cancer. In 59 patients with stage IV non-small cell lung cancer...
04:15 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Hello RNA

BioCentury’s analysis of new and emerging targets presented at this year’s AACR meeting reveals a surge in activity in non-coding RNAs, as researchers continue to expand target space. The results also reflect the ongoing high...
22:08 , Apr 4, 2017 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Asthma Patient sample, cell culture and mouse studies suggest stimulating T cells with activin A could help treat allergic asthma. In primary CD4 + T cells isolated from asthma patients and stimulated with mixed-grass...
20:41 , Nov 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Musculoskeletal

INDICATION: Osteoporosis Mouse studies suggest inhibiting GDF11 could help treat osteoporosis. In a mouse model of estrogen deficiency-induced bone loss, an anti-GDF11 mAb increased the number, thickness and volume of trabeculae in the distal femur...
07:00 , May 30, 2016 |  BC Week In Review  |  Clinical News

STM 434: Preliminary Phase I data

Preliminary data from 22 patients with advanced solid tumors in a 3-part, open-label, dose-escalation, U.S. Phase I trial showed that 0.25, 0.5, 0.75 and 1 mg/kg doses of IV STM 434 every 2-4 weeks led...